SARS-CoV-2 may induce liver injury due to the high expression of ACE2 in cholangiocytes, which may be potentiated by certain drugs used to treat COVID-19 such as antibiotics, remdesivir, tocilizumab, tofacitinib or dexamethasone [49,50]. Here, ACE2 is linked to COVID-19.